A novel series of indoline derivatives with imidazole and carboxyl moieties were synthesized and evaluated for their thromboxane A 2 (TXA 2 ) synthetase inhibiting, radical scavenging and anti-peroxidative activities. Among the compounds synthesized, 3-{5-substituted-3-[2-(imidazol-1-yl)ethyl]indolin-1-yl}propionic acids showed free radical scavenging activity and inhibitory effects on lipid-peroxidation of rat brain homogenate and on arachidonate-induced TXA 2 -dependent aggregation of rabbit platelets. The anti-platelet and anti-peroxidative activities were related to the lipophilicity of the 5-substituent. The 5-hexyloxy derivative (13) showed about 35-fold higher inhibitory activity on TXA 2 synthesis than that of ozagrel and about 100-fold higher activity on lipid peroxidation than that of a a-tocopherol. Compound 13 showed in vivo anti-thrombotic effect in mice and ex vivo anti-peroxidative activity in rats.
Thromboxane A 2 (TXA 2 ) is produced from prostaglandin H 2 (PGH 2 ) by TXA 2 synthetase in the arachidonic acid cascade, and has potent vasoconstricting and platelet aggregating activities. 1) Prostaglandin I 2 (PGI 2 ) is also produced from PGH 2 and has vasodilatory and antiaggregatory activities. Thus, excessive production of TXA 2 and/or imbalance of TXA 2 and PGI 2 play an important role in pathogenesis of ischemic cerebral and heart disease, thromboembolic disorders and atherosclerosis. [1] [2] [3] Selective TXA 2 synthetase inhibitors have been suggested to not only inhibit TXA 2 production but also to enhance PGI 2 synthesis since unused PGH 2 can be utilized by PGI 2 synthetase. Although a number of TXA 2 synthetase inhibitors have been reported, few have been successfully developed as clinically effective drugs for treatment of cerebral or coronary infarction or atherosclerosis. Superoxides and free radicals are also important pathogenetic factors in ischemic diseases and atherosclerosis. 4, 5) Antioxidants have been investigated as potential anti-ischemic drugs but their clinical efficacy has not been fully established. The arachidonic acid cascade and free radicals interact with each other in a complex manner. Free radicals are involved in enzymatic reactions in the arachidonic acid cascade and are released from endoperoxide metabolites of arachidonic acid. Furthermore, PGI 2 synthetase is more sensitive to inactivation by free radicals compared to TXA 2 synthetase, resulting in imbalance of PGI 2 and TXA 2 . Free radicals activate platelets and cause production of TXA 2 .
6) TXA 2 plays a role in oxygen radical generation in cerebral ischemia-reperfusion injury. 7) Therefore, simultaneous inhibition of TXA 2 and free radicals is expected to be more effective for protection against ischemic, thromboembolic and atherosclerotic disease than either alone. We reported previously that indapamide, a non-thiazide diuretic, has free radical scavenging activity, which is due to its indoline moiety, and protects PGI 2 synthetase from free radicals in vascular smooth muscle cells. 8) Known TXA 2 synthetase inhibitors have an aromatic ring, such as a benzene, a benzofuran or a benzothiophen, which bears two side chains with a carboxylic acid and a heterocycle, respectively ( Fig. 1) . [9] [10] [11] [12] [13] We designed a series of indoline derivatives with a carboxyl and an imidazole moiety to find a novel TXA 2 synthetase inhibitor with free radical scavenging activity.
Chemistry
Synthetic routes of the indoline-based imidazole derivatives are shown in Charts 1-3.
Chart 1 showed the general synthetic pathway for preparation of {3-[(imidazol-1-yl)alkyl]indolin-1-yl}alkylcarboxylic acid derivatives. The 5-substituted tryptophols (III, nϭ1) were prepared from the reaction between the appropriate phenyl hydrazines 14) (I) and 2,3-dihydrofuran with the Grandberg and Moskvina method. 15) The substituted tryptophols in other positions (4,6,7) (III, nϭ1) were prepared by condensation of oxalyl chloride with the appropriate indole 16) (II) to give glyoxylates followed by reduction with LiAlH 4 .
17)
The 5-substituted 3-(3-hydroxypropyl)indole (III, nϭ2) was prepared from ethyl 3-(5-hexyloxyindol-3-yl)propionate 18) by reduction with LiAlH 4 . The substituted tryptophols (III, nϭ1) and 3-(3-hydroxypropyl)indole (III, nϭ2) were re- duced with sodium cyanoborohydride (NaBH 3 CN) to corresponding indolines followed by protection with di-tert-butyl dicarbonate ((Boc) 2 O) to afford N-protected indoline derivatives (IV). Bromination of IV with CBr 4 and Ph 3 P followed by condensation with imidazole and deprotection with HCl to afford V. Target compounds (2, 7-9, 12-27) were obtained by condensation with ethyl acrylate or ethyl 3-bromopropionate followed by hydrolysis of ester precursors (VI) with NaOH. Compounds 10 and 11 were prepared from the 5-hydroxyindoline derivative (VII). Deprotection of VI (nϭ1, mϭ2, RϭOCH 2 C 6 H 5 ) was performed with trifluoroacetic acid (TFA) in anisole to afford the corresponding phenol (VII), which was condensed with the appropriate bromides followed by hydrolysis of ester precursors with NaOH to give 10 and 11.
A Novel Series of Thromboxane
Chart 2 shows the synthetic route of 3. 5-Bromoindoline derivative (28) was reacted with CuCN in N-methylpyrrolidone to afford 5-cyanoindoline derivative (29). Hydrolysis of 29 with conc. HCl gave the corresponding carboxylic acid (30), 19) which was protected with ester and (Boc) 2 O to give 31. Bromination of 31 with CBr 4 and Ph 3 P followed by condensation with imidazole gave 32, which was deprotected with NaOH and HCl to afford 3.
Chart 3 shows the synthetic route of the other indoline derivatives (4-6). The 4-substituted derivative (34a) was prepared from 33a by condensation with ethylene bromohydrin. The 5-or 6-substituted derivatives (34b, c) were obtained by reduction of the appropriate indoline carboxylate (33b, c) 19) with diisobutylaluminum hydride (DIBAL-H) or LiAlH 4 and protection with (Boc) 2 O. Bromination of 34a-c with CBr 4 and Ph 3 P followed by condensation with imidazole gave 35a-c, which were deprotected with HCl followed by condensation with ethyl bromoacetate or ethyl acrylate followed by hydrolysis of ester precursors with NaOH to afford target compounds 4-6.
Results and Discussion
In the present study, we synthesized a series of indoline derivatives and examined their biological activities to find novel TXA 2 synthetase inhibitors with free radical scavenging and anti-peroxidative activities. The inhibitory effects of compounds on the arachidonate-induced TXA 2 -dependent aggregation of rabbit platelets were determined to estimate their activities against TXA 2 synthetase. 20, 21) Selective TXA 2 synthetase inhibitors are known to partially inhibit arachidonate-induced aggregation without affecting adenosine 5Ј-diphosphate (ADP)-induced aggregation in rabbit platelets, while cyclooxygenase inhibitors abolish the arachidonate-induced aggregation. Free radical scavenging activity was evaluated using a,a-diphenyl-b-picrylhydrazyl (DPPH), a stable free radical. Anti-peroxidative activity was examined using rat brain homogenate. 8) Known TXA 2 synthetase inhibitors have two moieties bearing a heterocycle (imidazole, thiazole, pyridine etc.) and a carboxylic acid, attached to an aromatic ring such as benzene, benzofuran, benzothiophene, indole or indane. [9] [10] [11] [12] [13] First, we synthesized five compounds, in which imidazole and carboxylic acid moieties were introduced at different positions on the indoline ring and examined their activities (Table 1) . Compound 2 with an imidazole moiety at the 3-position and a carboxyl moiety at the 1-position showed an approximately 1.5-fold weaker inhibitory effect on arachidonate-induced aggregation than ozagrel, a selective TXA 2 synthetase inhibitor.
9) The shift of the imidazole moiety to the 5-position (compound 4) apparently enhanced the anti-platelet activity, but this was probably by inhibition of cyclooxygenase rather than TXA 2 synthetase, since aggregation was completely inhibited. The shift of the carboxyl moiety to the 5-position (compound 3) and the imidazole moiety to the 4-or 6-positions (compounds 5, 6), respectively, abolished the inhibitory activity on arachidonate-induced aggregation. The position of the imidazole and the carboxylic acid on the aromatic ring and the distance between these functional groups are important for the activity of TXA 2 synthetase inhibitors. [9] [10] [11] [12] [13] Among the indoline-based derivatives, the position of two functional groups and the distance between them in compound 2 may be more favorable for interaction with TXA 2 synthetase than those in the other four compounds (3) (4) (5) (6) . Compound 4 showed potent free radical scavenging activity comparable to those of ascorbic acid and a-tocopherol. Compounds 2 and 5 showed moderate free radical scavenging activity, while compounds 3 and 6 had weak activity. All the compounds in Table 1 showed little effect on lipid peroxidation. We assumed that these compounds were too hydrophilic to interact with the lipid-bilayer of the plasma membrane of rat brain homogenate. Indeed, ascorbic acid, a hydrophilic antioxidant, effectively scavenged free radicals but had no inhibitory effect on lipid peroxidation.
In the next set of experiments, compound 2 was structurally modified to enhance the inhibitory activity on TXA 2 synthesis and lipid peroxidation ( Table 2 ). Introduction of substituents including alkoxy, alkyl, alkenyl and alkylallyl at the 5-position increased the activity on arachidonate-induced aggregation. Among the alkoxy derivatives, the activity increased depending on the carbon number of the alkoxy group from 3 to 6 (compounds 7, 12, 13), while it was similar from 6 to 9 (compounds 13, 17, 19, 20) and was reduced at 12 (compound 21). Insertion of a double bond (compound 10), an oxygen atom (compound 11) or a cyclic structure (compounds 14, 18) tended to reduce the activity. The alkoxy moiety may tightly interact with the lipophilic region of the enzyme and enhance the inhibitory activity. All the compounds listed in Table 2 showed free radical scavenging activity similar to or stronger than that of compound 2. Introduction of lipophilic substituents markedly increased the inhibitory activity on lipid peroxidation except compound 11. Especially, the compounds with substituents containing more than 5 carbon atoms showed 24-to 318-fold stronger activity than that of a-tocopherol. Compounds with a longer and straight alkyl chain were more potent than those with a cycloalkyl or allylalkyl moiety. A long alkoxy chain seems to be favorable for interaction with the lipid-bilayer in plasma and microsomal membranes, as described for the synthetic ascorbate analogue CV-3611. 22) Finally, the effects of distance between the imidazole and carboxyl moieties and the position of the alkoxy side chain on both activities were investigated. The lengths of the alkyl chains bearing imidazole and carboxyl groups were changed ( Table 3) . Insertion of one methylene between the two functional groups decreased the inhibitory effect on arachidonateinduced platelet aggregation (13 vs. 22, 23), and introduction of two methylenes (13 vs. 24) markedly decreased the effect. For TXA 2 synthetase inhibitors, it is known that there is an optimal distance 8.5-9.0 Å between the nitrogen atom at the 1 position of the imidazole and the carboxyl carbon.
9) Changing the distance between the two functional groups had no effects on the free radical scavenging and anti-peroxidative activities (13, (22) (23) (24) . In compounds 20, 25-27, the effects of the position of the alkoxy moiety on the activities were examined. The shift of the nonyloxy group from the 5-position to the 6-or 7-position (20 vs. 26, 27) maintained the inhibitory activity against arachidonate-induced aggregation, but the shift to the 4-position resulted in a marked reduction 566 Vol. 49, No. 5 Table 2 . Structure and Biological Activities of 3-
Inhibition of LPO in this activity (20 vs. 25) . The anti-peroxidative activity was markedly reduced by the shift of the substituent to the 4-, 6-or 7-position. Thus, 3-{5-substituted-3-[2-(imidazol-1-yl)-ethyl]indolin-1-yl}propionic acid was confirmed to be a structure suitable for both inhibition of TXA 2 synthesis and lipid peroxidation.
The present results showed that normal alkoxy derivatives 13, 17, 19 and 20 have potent TXA 2 synthetase inhibitory and anti-peroxidative activities, indicating that the position of substituents on the indoline ring, the distance between the imidazolyl and the carboxyl group as well as the length of the alkoxy chain are favorable for both activities in these compounds. Smaller and less lipophilic compounds are desirable in terms of bioavailability and safety. Thus, compound 13 was selected and further evaluated. The IC 50 values of 13 and ozagrel for inhibition of TXA 2 synthesis in rabbit platelets were 0.043 and 1.50ϫ10 Ϫ6 M (nϭ4), respectively. Compound 13 but not ozagrel at a dose of 30 mg/kg (p.o.) significantly prevented the arachidonate-induced sudden death in mice (mortality: vehicle 100% and compound 13 40%, nϭ10, pϽ0.05, Fisher's exact method). Compound 13 (30 mg/kg, p.o.) significantly suppressed the ex vivo peroxidation in the rat plasma induced by FeSO 4 (malondialdehyde: 3.38 to 1.81 nmol/ml, nϭ6, pϽ0.05, Student's t-test). These results indicated that compound 13 exerted both anti-platelet and anti-peroxidative activities at the same dose in vivo.
Compound 13 is a potential therapeutic agent for the treatment of ischemic diseases by the dual inhibition of TXA 2 synthesis and lipid peroxidation. Further biological evaluation of 13 should be performed in experimental models of ishchemic disease, in which both TXA 2 and free radicals are considered to be involved.
Experimental
Melting points were measured on a Yamato capillary melting-point apparatus and are given uncorrected. IR spectra were taken with a JASCO IR-800 spectrometer.
1 H-NMR spectra were recorded at 90 MHz on a Hitachi R-1900 spectrometer using tetramethylsilane as an internal standard. For column chromatography, silica gel (Daisogel No.1001W, Daiso) was used.
2-(5-Hexyloxyindol-3-yl)ethanol (III, R‫-5؍‬O(CH 2 ) 5 CH 3 , n‫)1؍‬ To a solution of 4-hexyloxyphenylhydrazine hydrochloride (I, Rϭ4-O(CH 2 ) 5 CH 3 ) (7.0 g) in MeOH (200 ml) was added 2,3-dihydrofuran (4.3 ml) portionwise at 15°C. The reaction mixture was stirred at 50°C for 6 h and the solvent was removed in vacuo. Ϫ1 . The other 2-(5-substituted-indol-3-yl)ethanols (III) were prepared in a similar manner as described above. Yields and spectral data for these compounds are listed in Table 4 .
2-(6-Nonyloxyindol-3-yl)ethanol (III, R‫-6؍‬O(CH 2 ) 8 CH 3 , n‫)1؍‬ To a solution of 6-nonyloxyindole (II, Rϭ6-O(CH 2 ) 8 CH 3 ) (17.5 g) in Et 2 O (200 ml) was added oxalyl chloride (19.9 g) in Et 2 O (100 ml) at 5°C dropwise followed by stirring at 20°C for 5 h. After removal of the solvent in vacuo, the residue was dissolved in EtOH (200 ml) followed by stirring at 20°C for 15 h. After removal of the solvent in vacuo, the residue was dissolved in tetrahydrofuran (THF) (500 ml) and to the solution was added LiAlH 4 (18.0 g). The reaction mixture was refluxed for 3 h, then quenched with water and the product was extracted with AcOEt (200 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give III (Rϭ6-O(CH 2 ) 8 CH 3 , nϭ1) (9.0 g, yield 44%) as a solid. 
To a solution of 3-(5-hexyloxyindol-3-yl)propionic acid ethyl ester (18.0 g) in THF (200 ml) was added LiAlH 4 (10.5 g) portionwise at 5°C. The reaction mixture was stirred for 2 h at 20°C, then quenched with water and the product was extracted with AcOEt (200 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give III (Rϭ5-O(CH 2 ) 5 CH 3 , nϭ2) (14.5 g, yield 92%) as an oil. g) followed by stirring at 20°C for 10 h. The solvent was removed in vacuo to afford an oil, which was purified by column chromatography (nhexane-AcOEt) to yield IV (Rϭ5-O(CH 2 ) 5 CH 3 , nϭ1) (4.2 g, yield 91%) as an oil. 3 g ) and CBr 4 (5.9 g) in CH 3 CN (50 ml) was added Ph 3 P (4.6 g). The reaction mixture was stirred for 1 h at 20 °C and the solvent was removed in vacuo. The residue was dissolved in acetone (80 ml) and to the solution was added imidazole (8.0 g) and K 2 CO 3 (4.9 g) followed by refluxing for 20 h. After removal of the solvent in vacuo, the residue was dissolved in AcOEt (100 ml). The solution was washed with water and dried. After removal of the solvent in vacuo, the residue was dissolved in EtOH (30 ml). To the solution was added 10 N HCl in EtOH (26 ml) followed by stirring at 20°C for 2 h. After removal of the solvent in vacuo, 5-hexyloxy-3-[2-(imidazol-1-yl)ethyl]indoline hydrochloride was extracted with water (100 ml) and washed with AcOEt (50 ml). After neutralization with 4 N aq. NaOH, the extract with AcOEt (100 ml) was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give V (Rϭ5-O(CH 2 ) 5 CH 3 , nϭ1) (2.7 g, yield 73%) as an oil. 
3-{5-Hexyloxy-3-[2-(imidazol-1-yl)ethyl]indolin-1-yl}propionic Acid (13)
To a solution of VI (Rϭ5-O(CH 2 ) 5 CH 3 , nϭ1, mϭ2) (3.0 g) in 90% EtOH (30 ml) was added NaOH (0.92 g) followed by stirring at 20 °C for 3 h. After removal of the solvent in vacuo, the residue was dissolved in CHCl 3 (50 ml), the solution was washed with 5% aq. citric acid and dried. The solvent was removed in vacuo to give an oil, which was recrystallized from EtOH to give 13 ( 
. Compounds 2, 7-9, 12-27 were prepared in a similar manner as described just above. Physical properties and spectral data for these compounds are listed in Table 5 .
Ethyl 3-{5-Hydroxy-3-[2-(imidazol-1-yl)ethyl]indolin-1-yl}propionate (VII)
A solution of ethyl 3-{5-benzyloxy-3-[2-(imidazol-1-yl)ethyl]indolin-1-yl}propionate (VI, Rϭ5-OCH 2 C 6 H 5 , nϭ1, mϭ2) (18 g) in anisole (90 ml) and TFA (90 ml) was stirred at 70 °C for 16 h. After removal of solvent in vacuo, to the residue was added water (300 ml) and the soluble products were extracted with CHCl 3 (100 ml) and discarded. The aqueous solution was neutralized with aq. NaHCO 3 and the product was extracted with CHCl 3 (300 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give VII (12.1 g, yield 86%) as an oil. 1 
{5-Allyloxy-3-[2-(imidazol-1-yl)ethyl]indolin-1-yl}propionic Acid (10)
To a solution of VII (2.7 g) in EtOH (40 ml) was added potassium tert-butoxide (6.0 g) followed by stirring at 20°C for 0.5 h. To the reaction mixture was added allyl bromide (1.49 g) followed by stirring for 7 h at 90°C. After removal of solvent in vacuo, the residue was dissolved in AcOEt (200 ml). The solution was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give the ester of 10 (0.9 g, yield 30%) as an oil. To a solution of the ester (0.9 g) in 90% EtOH (30 ml) was added NaOH (0.36 g) followed by stirring at 20°C for 3 h. After removal of the solvent in vacuo, the residue was neutralized with 5% aq. citric acid and the product was extracted with CHCl 3 (50 ml). The extract was washed with water and dried. The solvent was removed in vacuo to give an oil, which was recrystallized from EtOH to give 10 (0.65 g, yield 78%) as crystals. mp 68-78°C:
1 H-NMR (DMSO-d 6 
3-Acetoxyethyl-1-acetyl-5-cyanoindoline (29)
A suspension of 28 (13.5 g) and CuCN (7.8 g) in N-methylpyrrolidone (40 ml) was stirred at 200°C for 2 h. The reaction mixture was cooled, diluted with AcOEt (300 ml), the solution was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to yield 29 (6.8 g, yield 60%) as a solid.
1 H-NMR (CDCl 3 ) 
3-(2-Hydroxyethyl)indoline-5-carboxylic Acid (30)
A solution of 29 (6.5 g) in conc. HCl (50 ml) was refluxed for 3 h. After concentrated to ca. 20 ml, the reaction mixture was adjusted to pH 10 with 10 N aq. NaOH. After removal of the insolubles by filtration, the aqueous solution was acidified to pH 4 with 1 N aq. HCl and the product was extracted with AcOEt (300 ml). The extracts were washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (toluene-AcOEt) to yield 30 (3.2 g, yield 65%) as a solid. (14.5 ml) and refluxed for 2 h. After removal of EtOH in vacuo, the residue was dissolved in CHCl 3 (100 ml) and the solution was washed with aq. NaHCO 3 and dried. After concentration of the solution to ca. 20 ml in vacuo, to the solution was added (Boc) 2 O (3.7 g) and triethylamine (1.7 g) followed by stirring at 60°C for 3 h. The reaction mixture was washed with 5% aq. citric acid, water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to yield 31 (4.8 g, yield 96%) as an oil. Ethyl 1-Boc-3-[2-(imidazol-1-yl) ethyl]indoline-5-carboxylate (32) To a solution of 31 (4.8 g) and CBr 4 (9.9 g) in CH 3 CN (100 ml) was added Ph 3 P (4.7 g). The reaction mixture was stirred for 2 h at 20°C. After removal of the solvent in vacuo, the residue was diluted with acetone (200 ml). To the solution was added imidazole (6.6 g) and K 2 CO 3 (5.3 g) followed by refluxing for 4 h. After removal of the solvent in vacuo, the residue was dissolved in AcOEt (300 ml). The solution was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 32 (3.2 g, yield 58%) as an oil. (20.7 g) in N,N-dimethylformamide (DMF) (100 ml) was stirred for 10 h at 60°C. The reaction mixture was diluted with AcOEt (500 ml), washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 34a (10.2 g, yield 56%) as a solid. 
1-Boc-5-hydroxymethylindoline (34b)
To a solution of ethyl indoline-5-carboxylate 33b (19.0 g) in dry benzene (200 ml) was added 0.1 M DIBAL-H in toluene solution (200 ml) dropwise at 20°C. The reaction mixture was stirred for 30 min at 40°C, then quenched with water and the product was extracted with CHCl 3 (500 ml). The extract was concentrated to ca. 100 ml in vacuo and to the solution was added (Boc) 2 O (43.2 g) followed by stirring for 10 h at 20°C. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (benzene-AcOEt) to give 34b (10 g, yield 40%) as an oil. 1 
1-Boc-5-(imidazol-1-yl)methylindoline (35b)
To a solution of 34b (10.0 g) and CBr 4 (26.7 g) in CH 3 CN (200 ml) was added Ph 3 P (10.5 g) at 10°C. The reaction mixture was stirred for 10 min at 20°C. To the reaction mixture was added imidazole (68.0 g) followed by stirring for 2 h at 20°C. After removal of the solvent in vacuo, the residue was dissolved in AcOEt (500 ml), the solution was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 35b (12.0 g, yield 95%) as an oil. 1 (12. 0 g) in CHCl 3 (300 ml) was added 10 N HCl in EtOH solution (40 ml). The reaction mixture was stirred for 2 h at 20°C. After neutralization with aq. NaHCO 3 , the organic layer was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 5-(imidazol-1-yl)methylindoline (3.6 g, yield 47%) as a solid. A mixture of 5-(imidazol-1-yl)methylindoline (1.0 g), ethyl bromoacetate (1.0 g) and K 2 CO 3 (1.4 g) in DMF (20 ml) was stirred at 20°C for 20 h. The reaction mixture was diluted with AcOEt (200 ml), the solution was washed with water and dried. The solvent was removed in vacuo to give an oil, which was purified by column chromatography (CHCl 3 -MeOH) to give 36b (0.8 g, yield 56%) as an oil. . Rabbit Platelet Aggregation (in Vitro) Male Japanese white rabbits (approximately 3 kg) were used. Blood was taken from the carotid artery under anesthesia with sodium pentobarbital (20 mg/kg, i.v.). Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were obtained by centrifugation at 1000 rpm for 10 min and at 3000 rpm for 10 min at 4°C, respectively. The platelet density of PRP was adjusted to 4ϫ10 5 cells/ml. Platelet aggregation was measured with an NKK Hema Tracer (Niko Bioscience). PRP was incubated with test compounds or ozagrel at 37°C for 1 min, followed by addition of arachidonic acid or ADP.
TXA 2 Synthesis in Washed Rabbit Platelets Rabbit blood was collected from the carotid artery under anesthesia with sodium pentobarbital and mixed with acid-citrate-dextrose (ACD) solution (sodium citrate 85 mM, citric acid 64 mM and dextrose 100 mM). PRP was obtained and the platelets were washed three times with Tyrode's solution. The platelets were finally suspended in Tyrode's solution at 10 5 cells/ml. The platelet suspension was incubated at 37°C for 10 min in the presence of aspirin (10 Ϫ5 M) and then further incubated with PGH 2 for 30 min. TXA 2 produced was determined as TXB 2 using a TXB 2 [ 3 H]RIA kit. Free Radical Scavenging DPPH, a stable free radical was dissolved at 10 Ϫ4 M in ethanol and incubated at 25°C for 20 min in the absence or presence of the synthesized compounds (10 Ϫ4 M) according to the method previously reported. 8) Remaining DPPH in the absence and presence of the test compounds was determined spectrophotometrically at a wavelength of 517 nm and % reduction by the compounds was calculated.
Lipid Peroxidation in Rat Brain Homogenate Production of lipidperoxide was determined as malondialdehyde (MDA) in the rat brain homogenate as reported previously 8) . Briefly, the cerebral cortex isolated from male SD rats (6-week old) was homogenized in ice-cold 50 mM phosphatebuffered saline (pH.7.4). The homogenate was centrifuged at 1300 g for 10 min at 4°C. The supernatant was incubated at 37°C for 30 min in the presence of vehicle or test compounds. The reaction was terminated by addition of 20% trichloroacetic acid, and the mixture was immediately centrifuged at 2000 g for 15 min at 4°C. The supernatant was heated at 100 °C for 15 min with thiobarbituric acid solution at pH 7.0. The optical absorbance of MDA was measured at 532 nm. The MDA level in medium before the assay was determined, and the net production of MDA during the incubation period in the presence of vehicle or test compounds was determined. Inhibition (%) of lipid peroxidation was calculated by comparison of MDA produced in the presence of vehicle and test compounds.
Plasma Lipid Peroxidation in Rats (ex Vivo) Male Wistar rats (7-week old) were used. Blood was taken from the abdominal aorta under anesthesia with sodium pentobarbital (50 mg/kg, i.p.) 1 h after administration of compound 13 (30 mg/kg) or vehicle. Plasma was seperated and incubated with FeSO 4 (5 mM) at 37°C for 3 h. The lipid peroxide levels were determined as MDA.
Arachidonate-Induced Death in Mice Male ddY mice (5-week old) were used. Arachidonic acid (100 mg/kg) was injected into the tail veins of mice and the mortality was observed for 180 min. Compound 13 and ozagrel (30 mg/kg) were administered orally 30 min before the injection of arachidonate.
